DaVita (NYSE:DVA) Posts Earnings Results, Beats Expectations By $0.54 EPS

05 May 2026, 20:44 by Scott Moore · The Cerbat Gem

DaVita (NYSE:DVA – Get Free Report) posted its earnings results on Tuesday. The company reported $2.87 EPS for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54, Zacks reports. The company had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The firm’s revenue for the quarter was up 6.0% on a year-over-year basis. During the same period in the previous year, the business earned $2.00 earnings per share. DaVita updated its FY 2026 guidance to 14.100-15.200 EPS.

Here are the key takeaways from DaVita’s conference call:

DaVita raised and narrowed its 2026 guidance — adjusted operating income to $2.15B–$2.25B and adjusted EPS to $14.10–$15.20 — attributing the increase mainly to higher volume and lower patient-care costs.
Treatment volume guidance was lifted to +25–50 bps (≈+50–75 bps normalized treatments per day) driven by better-than-forecast mortality and patient transfers from Fresenius clinic closures.
Q1 results beat expectations with adjusted operating income of $482M, adjusted EPS of $2.87, and free cash flow of $140M; the company repurchased ~5M shares and ended the quarter with leverage at 3.34x EBITDA.
Management is investing in data, a proprietary EMR, and AI applications (e.g., Schedule Hub) to boost productivity and clinical outcomes, but benefits are early and contributed to a ~13% increase in G&A versus prior year.
ACA open-enrollment is trending slightly more favorable than the prior ~$40M headwind estimate, but a shift toward lower-tier bronze plans could raise patient out-of-pocket costs and modestly pressure revenue per treatment.

DaVita Trading Up 1.9%

Shares of NYSE DVA traded up $2.90 during midday trading on Tuesday, hitting $156.98. The company’s stock had a trading volume of 1,992,540 shares, compared to its average volume of 610,383. The business’s 50 day moving average is $151.30 and its two-hundred day moving average is $131.73. DaVita has a 12-month low of $101.00 and a 12-month high of $159.42. The firm has a market cap of $10.49 billion, a P/E ratio of 15.84, a price-to-earnings-growth ratio of 0.54 and a beta of 0.84.

Wall Street Analysts Forecast Growth

DVA has been the topic of several analyst reports. Truist Financial set a $158.00 price objective on DaVita in a research note on Thursday, February 5th. UBS Group boosted their price objective on DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a research note on Wednesday, February 4th. Barclays boosted their price objective on DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 3rd. Zacks Research cut DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Finally, Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $155.80.

View Our Latest Research Report on DVA

DaVita News Summary

Here are the key news stories impacting DaVita this week:

Positive Sentiment: Q1 earnings and revenue beat street estimates; EPS $2.87 vs. consensus and revenue topped expectations, showing operational strength. DaVita HealthCare (DVA) Tops Q1 Earnings and Revenue Estimates
Positive Sentiment: Company raised its annual adjusted profit forecast, citing steady/strong demand for dialysis services — a clear driver for higher forward earnings expectations. DaVita lifts annual profit forecast on strong demand for dialysis services
Positive Sentiment: Company commentary and PR emphasize clinical performance and operating rigor, reinforcing confidence in recurring dialysis revenue and margin durability. DaVita Inc. 1st Quarter 2026 Results
Neutral Sentiment: Guidance range of $14.10–$15.20 roughly lines up with consensus (≈$14.13 midpoint), so while management raised the top-line outlook, the midpoint is close to expectations — limits the surprise factor. MarketBeat Q1 release & guidance
Neutral Sentiment: Elevated intraday trading volume (~2M vs. ~985k average) indicates increased attention and liquidity, which can amplify price moves in either direction. DaVita’s Q1 CY2026 beats on revenue
Negative Sentiment: Despite the beat, reported net margin was modest (≈5.5%) and the company showed a negative return on equity figure, which may concern some investors about capital structure or one-time items; watch commentary from the call for drivers. DaVita HealthCare: Q1 Earnings Snapshot

Institutional Investors Weigh In On DaVita

Several hedge funds and other institutional investors have recently modified their holdings of the business. Invesco Ltd. grew its stake in DaVita by 2.0% in the third quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock worth $223,122,000 after purchasing an additional 32,358 shares in the last quarter. Morgan Stanley grew its stake in DaVita by 5.1% in the fourth quarter. Morgan Stanley now owns 1,477,045 shares of the company’s stock worth $167,807,000 after purchasing an additional 71,156 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in DaVita by 0.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,089,100 shares of the company’s stock worth $123,733,000 after purchasing an additional 3,507 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in DaVita by 109.7% in the third quarter. Arrowstreet Capital Limited Partnership now owns 553,809 shares of the company’s stock worth $73,585,000 after purchasing an additional 289,725 shares in the last quarter. Finally, Corient Private Wealth LLC grew its stake in DaVita by 1,493.1% in the fourth quarter. Corient Private Wealth LLC now owns 358,299 shares of the company’s stock worth $40,706,000 after purchasing an additional 335,809 shares in the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

About DaVita

(Get Free Report)

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.